Clinical trials: IBS-D (Diarrhea-predominant)
Irritable Bowel Syndrome
Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
The objectives of this study are (1) to determine the efficacy of fecal microbiota transplantation (FMT), given as oral capsules, compared with placebo for the treatment of refractory diarrhea-predominant irritable bowel syndrome…
- Trial name
- NCT02328547
- Testing
- Fecal microbiota transplantation capsules
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Montefiore Medical Center
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
The purpose of this study is to evaluate the efficacy of DNK333 compared to placebo for relieving symptoms of IBS-D in female patients.
- Trial name
- NCT00394173
- Testing
- DNK333
- Where
- 43 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- Novartis
Diarrhea Predominant Irritable Bowel Syndrome
Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D
Will Ranolazine improve bowel function and abdominal pain in human subjects with IBS-D?
- Trial name
- Ranolazine (NCT02239926)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Diarrhea-Predominant Irritable Bowel Syndrome
Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
The goal of this clinical trial is to test the efficacy and safety of the Chinese patent medicine Changyanning Tablet in the patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).
- Trial name
- NCT05687435
- Testing
- Changyanning tablet
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Mei Han
Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome
Safety and Efficacy of a Probiotic Supplement in IBS-D
This study aims to assess the safety and efficacy of a single probiotic strain on symptom severity in adults with diarrhea-predominant Irritable Bowel Syndrome (IBS-D).
- Trial name
- IBIS (NCT05754177)
- Testing
- Probiotic
- Where
- Slovenia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company
IBS-D and Functional Dyspepsia
Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia
Primary Objective: To confirm the efficacy of the probiotic product Healthy Trinity (retail label)/Trenev Trio (professional label) in the improvement of symptoms in adult patients with diarrhea-predominant irritable bowel…
- Trial name
- NCT01268618
- Testing
- Probiotic
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sprim Advanced Life Sciences
Diarrhea-predominant Irritable Bowel Syndrome, Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Evaluation of the Efficacy and Safety of Gelsectan in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome
This clinical study aims to investigate the effectiveness and safety of Gelsectan, a treatment containing xyloglucan, in adults diagnosed with diarrhea-predominant irritable bowel syndrome (IBS-D) in Vietnam.
- Trial name
- GELIBS (NCT07000383)
- Testing
- Gelsectan, Antispasmodic Agent
- Where
- Vietnam
- Volunteers
- 90 people
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Irritable Bowel Syndrome
Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
This study will examine the efficacy, safety and tolerability of oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
- Trial name
- NCT00189696
- Testing
- YM060
- Where
- 4 sites in Japan
- Sponsor
- Astellas Pharma Inc
IBS-D (Diarrhea-predominant)
Bacillus Coagulans Based Product in IBS-Diarrhea
This is a prospective, randomized, double-blind, placebo-controlled, parallel-group interventional clinical trial designed to evaluate the efficacy and safety of a Bacillus coagulans-based product in adult patients with mild to…
- Trial name
- NCT07520422
- Testing
- Probiotic Arm
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Bioagile Therapeutics Pvt. Ltd.
Irritable Bowel Syndrome With Diarrhea
Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients.
- Trial name
- NCT06153420
- Testing
- CIN-103
- Where
- 53 sites in United States
- Volunteers
- 421 people
- Sponsor
- CinPhloro Pharma, LLC
IBS, Diarrhea Predominant
Transcutaneous Electrical Acustimulation for IBS-D: A Multicenter Study
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits.
- Trial name
- NCT07425145
- Testing
- Portable stimulator
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First People's Hospital of Foshan
Non-erosive Reflux Disease, Diarrhea-Predominant Irritable Bowel Syndrome
Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D
Non-erosive reflux disease（NERD）and Diarrhea-Predominant Irritable Bowel Syndrome（IBS-D）are both the common refractory gastrointestinal diseases.
- Trial name
- NCT05369884
- Testing
- WPQW granule, WPQW granule simulant
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
IBS - Irritable Bowel Syndrome, Gut Microbiota
Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D
We will use the latest Rome IV criteria to recruit IBS-D patients and evaluate the effects of repeated treatment with rifaximin and sequential treatment with rifaximin and probiotics on different symptoms and quality of life.
- Trial name
- NCT04074421
- Testing
- Rifaximin, Probiotic Formula
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Irritable Bowel Syndrome
Multi-strain Probiotic in the Management of IBS-D
1. To assess the effect of multistrain probiotics on abdominal pain using a validated symptom severity score in IBS patients. 2.
- Trial name
- NCT03251625
- Testing
- Probiotic Formula Capsule
- Volunteers
- 400 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome With Diarrhea (IBS-D)
Curcumin, Vitamin D and Green Tea in IBS-D
Irritable Bowel Syndrome (IBS) is a highly prevalent condition of the gastrointestinal tract that has significant impact on sufferer's quality of life. The diarrhoea variant (IBS-D) makes up around one third of all IBS sufferers.
- Trial name
- NCT07052890
- Testing
- Curcumin, vitamin d and green tea extract
- Where
- 3 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- Dr Anthony Hobson
Diarrhea-predominant Irritable Bowel Syndrome
Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D
To evaluate the safety and effectiveness of oral nutritional therapy Serum-Derived Bovine Immunoglobulin (SBI) on nutritional status, epithelial barrier function, and mucosal expression of pivotal genes including tight junction…
- Trial name
- NCT02163213
- Testing
- Serum-derived bovine immunoglobulin protein isolate (SBI)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Diarrhea Predominant Irritable Bowel Syndrome
A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
This trial will evaluate the effect of ASP7147 on daily abdominal pain due to IBS-D during 4 weeks of treatment. It will also evaluate safety and tolerability in patients with IBS-D over the 4-week treatment period.
- Trial name
- NCT01896583
- Testing
- ASP7147
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Seldar Pharma, Inc.
Irritable Bowel Syndrome
A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients
A study to verify the superiority of YM060 (ramosetron) to placebo for female patients with diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.
- Trial name
- NCT01274000
- Testing
- YM060
- Where
- 4 sites in Japan
- Volunteers
- 409 people
- Sponsor
- Astellas Pharma Inc
IBS-D (Diarrhea-predominant)
Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D
Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder affecting 15-20% of people in industrialized countries, often presenting as abdominal discomfort, pain, and altered bowel habits, significantly impacting…
- Trial name
- PROREDI (NCT06676514)
- Testing
- Probiotic Clostridium butyricum CBM588®, Standard of care IBS-D treatment
- Where
- Italy
- Volunteers
- 405 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Diarrhea Predominant Irritable Bowel Syndrome
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
The purpose of this study is to determine whether asimadoline is safe and effective at treating D-IBS.
- Trial name
- NCT01100684
- Testing
- Asimadoline
- Where
- 142 sites in United States
- Volunteers
- 611 people
- Sponsor
- Tioga Pharmaceuticals